TEVA Pharmaceutical (NASDAQ: TEVA), the world's biggest generic drugmaker, reported that third-quarter net income fell to $525 million, or 64 cents a share, from $606 million, or 74 cents, in the year-earlier period. Sales reached $2.37 billion from $2.29 billion. Consensus estimates of 63 cents of profit on sales of $2.41 billion was expected. While TEVA was a bit light on the revenue line, it beat by a penny on EPS, in large part due to stronger than expected margins.

With a very strong pipeline, and expanding margins, TEVA continues to be the leading large pharma play out there. The stock is trading down today for two reasons. Up more than 50% year to date, the stock was priced for a blowout earnings report, which we didn't get. More importantly, CFO Dan Suesskind announced his retirement. In the company for over 30 years, he is the face of the company to investors, and his departure leaves many nervous. Hi replacement, current Checkpoint (NASDAQ: CHKP) CFO, Eyal Desheh, is no slouch. He knows TEVA well, having worked there for six years and as CFO of a NASDAQ 100 high-tech company, he is well-known on the Street.

For those looking for a long-term pharma play, consider buying TEVA on any weakness.

Disclosure: Author holds both TEVA and CHKP as of 10/30/07.

Aaron Katsman is the lead Portfolio Manager and Managing Director of America Israel Investment Associates, LLC. and Senior Editor of IsraelNewsletter.com.

Visit AOL Money & Finance for more earnings coverage